E
Accelerate Diagnostics, Inc.
AXDX
$0.77
$0.03354.55%
E
Sell
1/5/2024Downgrade
Accelerate Diagnostics, Inc. (AXDX) was downgraded to E+ from D- on 1/5/2024 due to a decline in the volatility index.
Accelerate Diagnostics, Inc. (AXDX) was downgraded to E+ from D- on 1/5/2024 due to a decline in the volatility index.
D
Sell
12/21/2023Upgraded
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D- from E+ on 12/21/2023 due to an increase in the volatility index.
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D- from E+ on 12/21/2023 due to an increase in the volatility index.
E
Sell
12/5/2023Downgrade
Accelerate Diagnostics, Inc. (AXDX) was downgraded to E+ from D- on 12/5/2023 due to a decline in the volatility index and total return index.
Accelerate Diagnostics, Inc. (AXDX) was downgraded to E+ from D- on 12/5/2023 due to a decline in the volatility index and total return index.
D
Sell
11/15/2023Upgraded
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D- from E+ on 11/15/2023 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$2.9735 to $0.06, operating cash flow increased 23.73% from -$10.82M to -$8.25M, and total revenue increased 12.94% from $2.92M to $3.3M.
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D- from E+ on 11/15/2023 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$2.9735 to $0.06, operating cash flow increased 23.73% from -$10.82M to -$8.25M, and total revenue increased 12.94% from $2.92M to $3.3M.
E
Sell
10/30/2023Downgrade
Accelerate Diagnostics, Inc. (AXDX) was downgraded to E+ from D- on 10/30/2023 due to a decline in the volatility index.
Accelerate Diagnostics, Inc. (AXDX) was downgraded to E+ from D- on 10/30/2023 due to a decline in the volatility index.
D
Sell
10/11/2023Upgraded
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D- from E+ on 10/11/2023 due to an increase in the volatility index and total return index.
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D- from E+ on 10/11/2023 due to an increase in the volatility index and total return index.
E
Sell
9/25/2023Downgrade
Accelerate Diagnostics, Inc. (AXDX) was downgraded to E+ from D- on 9/25/2023 due to a decline in the volatility index.
Accelerate Diagnostics, Inc. (AXDX) was downgraded to E+ from D- on 9/25/2023 due to a decline in the volatility index.
D
Sell
9/6/2023Upgraded
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D- from E+ on 9/6/2023 due to an increase in the volatility index.
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D- from E+ on 9/6/2023 due to an increase in the volatility index.
E
Sell
8/18/2023Downgrade
Accelerate Diagnostics, Inc. (AXDX) was downgraded to E+ from D- on 8/18/2023 due to a decline in the volatility index and total return index.
Accelerate Diagnostics, Inc. (AXDX) was downgraded to E+ from D- on 8/18/2023 due to a decline in the volatility index and total return index.
D
Sell
8/15/2023Upgraded
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D- from E+ on 8/15/2023 due to an increase in the volatility index and total return index.
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D- from E+ on 8/15/2023 due to an increase in the volatility index and total return index.
E
Sell
3/14/2023Downgrade
Accelerate Diagnostics, Inc. (AXDX) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
Accelerate Diagnostics, Inc. (AXDX) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/9/2023Upgraded
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D from E+ on 02/09/2023.
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Accelerate Diagnostics, Inc. (AXDX) was downgraded to E+ from D on 2/8/2023 due to a decline in the growth index. Total revenue declined 23.34% from $3.86M to $2.96M, and operating cash flow declined 4.42% from -$13M to -$13.57M.
Accelerate Diagnostics, Inc. (AXDX) was downgraded to E+ from D on 2/8/2023 due to a decline in the growth index. Total revenue declined 23.34% from $3.86M to $2.96M, and operating cash flow declined 4.42% from -$13M to -$13.57M.
D
Sell
5/17/2022Upgraded
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D from D- on 5/17/2022 due to a significant increase in the growth index and volatility index. Earnings per share increased from -$0.3447 to -$0.2094, and EBIT increased 18.12% from -$19.41M to -$15.9M.
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D from D- on 5/17/2022 due to a significant increase in the growth index and volatility index. Earnings per share increased from -$0.3447 to -$0.2094, and EBIT increased 18.12% from -$19.41M to -$15.9M.
D
Sell
5/5/2022Upgraded
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index.
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Accelerate Diagnostics, Inc. (AXDX) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and total return index.
Accelerate Diagnostics, Inc. (AXDX) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and total return index.
D
Sell
3/21/2022Downgrade
Accelerate Diagnostics, Inc. (AXDX) was downgraded to D- from D on 3/21/2022 due to a substantial decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.147 to -$0.3447, and EBIT declined 33.58% from -$14.53M to -$19.41M.
Accelerate Diagnostics, Inc. (AXDX) was downgraded to D- from D on 3/21/2022 due to a substantial decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.147 to -$0.3447, and EBIT declined 33.58% from -$14.53M to -$19.41M.
D
Sell
11/22/2021Upgraded
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D from D- on 11/22/2021.
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D from D- on 11/22/2021.
D
Sell
11/8/2021Downgrade
Accelerate Diagnostics, Inc. (AXDX) was downgraded to D- from D on 11/8/2021 due to a decline in the total return index and volatility index.
Accelerate Diagnostics, Inc. (AXDX) was downgraded to D- from D on 11/8/2021 due to a decline in the total return index and volatility index.
D
Sell
10/19/2020Downgrade
Accelerate Diagnostics, Inc. (AXDX) was downgraded to D from D+ on 10/19/2020 due to a decline in the volatility index and total return index.
Accelerate Diagnostics, Inc. (AXDX) was downgraded to D from D+ on 10/19/2020 due to a decline in the volatility index and total return index.
D
Sell
10/2/2020Upgraded
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D+ from D on 10/2/2020 due to an increase in the volatility index, growth index and total return index. Operating cash flow increased 44.32% from -$17.6M to -$9.8M, EBIT increased 11.31% from -$17.73M to -$15.73M, and earnings per share increased from -$0.3886 to -$0.3468.
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D+ from D on 10/2/2020 due to an increase in the volatility index, growth index and total return index. Operating cash flow increased 44.32% from -$17.6M to -$9.8M, EBIT increased 11.31% from -$17.73M to -$15.73M, and earnings per share increased from -$0.3886 to -$0.3468.
D
Sell
5/1/2020Upgraded
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the growth index and valuation index. Total revenue increased 52.8% from $2.27M to $3.47M, and operating cash flow increased 20.16% from -$17.37M to -$13.87M.
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the growth index and valuation index. Total revenue increased 52.8% from $2.27M to $3.47M, and operating cash flow increased 20.16% from -$17.37M to -$13.87M.
D
Sell
11/8/2018Downgrade
Accelerate Diagnostics, Inc. (AXDX) was downgraded to D- from D on 11/8/2018 due to a noticeable decline in the solvency index, volatility index and total return index. Debt to equity increased from 1.22 to 1.52.
Accelerate Diagnostics, Inc. (AXDX) was downgraded to D- from D on 11/8/2018 due to a noticeable decline in the solvency index, volatility index and total return index. Debt to equity increased from 1.22 to 1.52.
D
Sell
8/14/2018Upgraded
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D from D- on 8/14/2018 due to an increase in the efficiency index, growth index and volatility index. Total revenue increased 111.24% from $801 to $1.69M, total capital increased 2.31% from $205.64M to $210.39M, and EBIT increased 1.97% from -$20.83M to -$20.42M.
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D from D- on 8/14/2018 due to an increase in the efficiency index, growth index and volatility index. Total revenue increased 111.24% from $801 to $1.69M, total capital increased 2.31% from $205.64M to $210.39M, and EBIT increased 1.97% from -$20.83M to -$20.42M.
D
Sell
8/9/2016Downgrade
Accelerate Diagnostics, Inc. (AXDX) was downgraded to D- from D on 8/9/2016 due to a decline in the efficiency index, growth index and solvency index. Total revenue declined 87.73% from $163 to $20, earnings per share declined from -$0.2944 to -$0.35, and net income declined 18.52% from -$15.07M to -$17.87M.
Accelerate Diagnostics, Inc. (AXDX) was downgraded to D- from D on 8/9/2016 due to a decline in the efficiency index, growth index and solvency index. Total revenue declined 87.73% from $163 to $20, earnings per share declined from -$0.2944 to -$0.35, and net income declined 18.52% from -$15.07M to -$17.87M.
D
Sell
8/4/2016Upgraded
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D from D- on 8/4/2016 due to an increase in the total return index and volatility index.
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D from D- on 8/4/2016 due to an increase in the total return index and volatility index.
D
Sell
7/20/2016Downgrade
Accelerate Diagnostics, Inc. (AXDX) was downgraded to D- from D on 7/20/2016 due to a decline in the valuation index.
Accelerate Diagnostics, Inc. (AXDX) was downgraded to D- from D on 7/20/2016 due to a decline in the valuation index.
D
Sell
6/2/2016Upgraded
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D from D- on 6/2/2016 due to an increase in the volatility index and total return index.
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D from D- on 6/2/2016 due to an increase in the volatility index and total return index.
D
Sell
5/11/2016Downgrade
Accelerate Diagnostics, Inc. (AXDX) was downgraded to D- from D on 5/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Net income declined 14.52% from -$13.16M to -$15.07M, and total capital declined 10.05% from $133.03M to $119.66M.
Accelerate Diagnostics, Inc. (AXDX) was downgraded to D- from D on 5/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Net income declined 14.52% from -$13.16M to -$15.07M, and total capital declined 10.05% from $133.03M to $119.66M.
D
Sell
11/5/2014Downgrade
Accelerate Diagnostics, Inc. (AXDX) was downgraded to D from D+ on 11/5/2014 due to a decline in the total return index, solvency index and efficiency index. Total capital declined 8.19% from $78.94M to $72.47M, and the quick ratio declined from 35.13 to 34.91.
Accelerate Diagnostics, Inc. (AXDX) was downgraded to D from D+ on 11/5/2014 due to a decline in the total return index, solvency index and efficiency index. Total capital declined 8.19% from $78.94M to $72.47M, and the quick ratio declined from 35.13 to 34.91.
D
Sell
8/1/2014Upgraded
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D+ from D on 8/1/2014 due to an increase in the efficiency index, solvency index and volatility index. Total capital increased 102.01% from $39.08M to $78.94M, net income increased 56.71% from -$5.2M to -$8.15M, and the quick ratio increased from 22.61 to 35.13.
Accelerate Diagnostics, Inc. (AXDX) was upgraded to D+ from D on 8/1/2014 due to an increase in the efficiency index, solvency index and volatility index. Total capital increased 102.01% from $39.08M to $78.94M, net income increased 56.71% from -$5.2M to -$8.15M, and the quick ratio increased from 22.61 to 35.13.
NASDAQ
04/18/2024 4:00PM Eastern
Quotes delayed
